Literature DB >> 10835681

Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells.

R Abonour1, D A Williams, L Einhorn, K M Hall, J Chen, J Coffman, C M Traycoff, A Bank, I Kato, M Ward, S D Williams, R Hromas, M J Robertson, F O Smith, D Woo, B Mills, E F Srour, K Cornetta.   

Abstract

Pre-clinical studies indicate that efficient retrovirus-mediated gene transfer into hematopoietic stem cells and progenitor cells can be achieved by co-localizing retroviral particles and target cells on specific adhesion domains of fibronectin. In this pilot study, we used this technique to transfer the human multidrug resistance 1 gene into stem and progenitor cells of patients with germ cell tumors undergoing autologous transplantation. There was efficient gene transfer into stem and progenitor cells in the presence of recombinant fibronectin fragment CH-296. The infusion of these cells was associated with no harmful effects and led to prompt hematopoietic recovery. There was in vivo vector expression, but it may have been limited by the high rate of aberrant splicing of the multidrug resistance 1 gene in the vector. Gene marking has persisted more than a year at levels higher than previously reported in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835681     DOI: 10.1038/76225

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  36 in total

1.  Cautious advance. Gene therapy is more complex than anticipated.

Authors:  A Fischer
Journal:  EMBO Rep       Date:  2000-10       Impact factor: 8.807

Review 2.  Current gene therapy for stomach carcinoma.

Authors:  C T Xu; L T Huang; B R Pan
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

Review 3.  Gene-marking studies of hematopoietic cells.

Authors:  C M Bollard; H E Heslop; M K Brenner
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 4.  Selective expansion of transduced cells for hematopoietic stem cell gene therapy.

Authors:  Akihiro Kume; Yutaka Hanazono; Hiroaki Mizukami; Takashi Okada; Keiya Ozawa
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 5.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

Review 6.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

7.  Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.

Authors:  Olga S Kustikova; Hartmut Geiger; Zhixiong Li; Martijn H Brugman; Stuart M Chambers; Chad A Shaw; Karin Pike-Overzet; Dick de Ridder; Frank J T Staal; Gottfried von Keudell; Kerstin Cornils; Kalpana Jekumar Nattamai; Ute Modlich; Gerard Wagemaker; Margaret A Goodell; Boris Fehse; Christopher Baum
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

8.  Retrovirus-associated heparan sulfate mediates immobilization and gene transfer on recombinant fibronectin.

Authors:  Pedro Lei; Bharat Bajaj; Stelios T Andreadis
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.

Authors:  J A Schroeder; Y Chen; J Fang; D A Wilcox; Q Shi
Journal:  J Thromb Haemost       Date:  2014-07-17       Impact factor: 5.824

Review 10.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.